

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 February 2008 (14.02.2008)

PCT

(10) International Publication Number
WO 2008/019147 A3

(51) International Patent Classification:

A61K 38/22 (2006.01) A61P 3/10 (2006.01)
A61K 38/26 (2006.01) A61P 9/00 (2006.01)

(21) International Application Number:

PCT/US2007/017621

(22) International Filing Date: 6 August 2007 (06.08.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/835,436 4 August 2006 (04.08.2006) US

(71) Applicants (for all designated States except US):

AMYLIN PHARMACEUTICALS, INC. [US/US];
9360 Towne Centre Drive, San Diego, California 92121
(US). ELI LILLY AND COMPANY [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KIM, Dennis
[US/US]; 9360 Towne Centre Drive, San Diego, Cali-
fornia 92121 (US). TRAUTMANN, Michael [DE/DE];
Fueerberg 16a, D-22393 Hamburg (DE).

(74) Common Representative: AMYLIN PHARMACEU-
TICALS, INC.; 9360 Towne Centre Drive, San Diego,
California 92121 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,
ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK,
LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW,
MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available):

ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

11 June 2009

(54) Title: USE OF EXENDINS, EXENDIN AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR ALTERING THE CONCENTRATION OF FIBRINOGEN

(57) Abstract: The present invention relates to altering the concentration of fibrinogen, specifically, for example, by decreasing fibrinogen concentration. The present invention also relates to methods for improving the cardiovascular risk profile of a subject by decreasing fibrinogen concentration.



WO 2008/019147 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/017621

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K38/22 A61K38/26 A61P3/10 A61P9/00				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K A61P				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, FSTA, BIOSIS, EMBASE, WPI Data				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	HOOD ET AL: "Use of exenatide in patients with type 2 diabetes" DIABETES SPECTRUM, vol. 19, July 2006 (2006-07), pages 181-186, XP002524062 * See page 181 (Abstract) and page 183 (Clinical use of exenatide) * -----	1-100		
Y	GARDINER ET AL: "Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats" THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 316, February 2006 (2006-02), pages 852-859, XP002524063 * See page 852 (Abstract) * ----- -/--	1-100		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.				
* Special categories of cited documents :				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family </td> </tr> </table>			*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family			
Date of the actual completion of the international search	Date of mailing of the international search report			
17 April 2009	29/04/2009			
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Korsner, Sven-Erik			

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/017621

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DEACON: "Therapeutic strategies based on glucagon-like peptide 1" DIABETES, vol. 53, 2004, pages 2181-2189, XP002524064 * See pages 2182-2183 (GLP-1, exendin-4 and diabetes) *	1-100
A	US 2005/101537 A1 (BEELEY ET AL) 12 May 2005 (2005-05-12) * See Abstract, [0010], [0020], and [0023] *	1-100
P,X	KAPITZA ET AL: "Long-term treatment with exenatide improved post-prandial glycaemic control and was associated with a shift from small to large HDL and LDL particles" DIABETOLOGIA (SUPPLEMENT 1), vol. 49, September 2006 (2006-09), pages 140-141, XP002524010 * See Abstract 0224 (fibrinogen) *	1-100
P,A	TUTUNCU ET AL: "Exendin-4 rapidly activates eNOS and protects human coronary artery endothelial cells against gluco-lipoapoptosis" DIABETOLOGIA (SUPPLEMENT 1), vol. 49, September 2006 (2006-09), page 146, XP002524011 * See Abstract 0232 (GLP-1, coronary artery disease) *	1-100
P,A	COURRÈGES ET AL: "Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study" DIABETOLOGIA (SUPPLEMENT 1), vol. 49, September 2006 (2006-09), page 4, XP002524013 * See Abstract 0003 (GLP-1) "	1-100
P,A	LINNEBJERG ET AL: "Exenatide delays gastric emptying and reduces post-prandial glucose in type 2 diabetes" DIABETOLOGIA (SUPPLEMENT 1), vol. 49, September 2006 (2006-09), page 140, XP002524012 * See Abstract 0223 (GLP-1) *	1-100

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2007/017621

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2005101537 A1	12-05-2005	US 2005059601 A1	17-03-2005